KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Depreciation & Amortization (CF) (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of Depreciation & Amortization (CF) readings, the most recent being $394000.0 for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 27.51% to $394000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.4 million, a 11.48% increase, with the full-year FY2025 number at $1.4 million, up 11.48% from a year prior.
  • Depreciation & Amortization (CF) hit $394000.0 in Q4 2025 for Biocryst Pharmaceuticals, up from $335000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $423000.0 in Q4 2023 to a low of $171000.0 in Q4 2021.
  • Median Depreciation & Amortization (CF) over the past 5 years was $330000.0 (2025), compared with a mean of $325200.0.
  • Biggest five-year swings in Depreciation & Amortization (CF): skyrocketed 131.58% in 2022 and later dropped 26.95% in 2024.
  • Biocryst Pharmaceuticals' Depreciation & Amortization (CF) stood at $171000.0 in 2021, then skyrocketed by 131.58% to $396000.0 in 2022, then rose by 6.82% to $423000.0 in 2023, then dropped by 26.95% to $309000.0 in 2024, then grew by 27.51% to $394000.0 in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $394000.0 (Q4 2025), $335000.0 (Q3 2025), and $329000.0 (Q2 2025) per Business Quant data.